Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-19T06:36:22.693Z Has data issue: false hasContentIssue false

Chapter 13 - Treatment of hemifacial spasm

Published online by Cambridge University Press:  05 February 2014

Karen Frei
Affiliation:
The Parkinson and Movement Disorder Institute, Orange Coast Memorial Center, Fountain Valley, CA, USA
Daniel Truong
Affiliation:
The Parkinson’s and Movement Disorders Institute, Fountain Valley, California
Dirk Dressler
Affiliation:
Department of Neurology, Hannover University Medical School
Mark Hallett
Affiliation:
George Washington University School of Medicine and Health Sciences, Washington, DC
Christopher Zachary
Affiliation:
Department of Dermatology, University of California, Irvine
Get access

Summary

Introduction

Hemifacial spasm (HFS) is characterized as involuntary irregular clonic or tonic movements of the facial muscles innervated by cranial nerve VII on one side of the face and is most often a result of vascular compression of the facial nerve at the root exit zone (Wang and Jankovic, 1998). Facial muscle twitches usually begin in the periocular region and can progress to involve the cheek and perioral muscles. Hemifacial spasm is almost always unilateral; however, when bilateral, the two sides are always asynchronous. Atypical cases have been reported to initiate in the orbicularis oris and buccinator muscles and gradually spread upward to involve the orbicularis oculi (Ryu et al., 1998). At times, with involvement of the platysma muscle, a tremor-like appearance of the head can develop (Frei and Truong, 2008). Muscles involved in HFS include the orbicularis oculi, frontalis (rarely), corrugator, nasalis, zygomaticus, risorius, orbicularis oris and sometimes the platysma (Fig. 13.1).

Hemifacial spasm is more prevalent in females, commonly begins in the fifth decade and tends to have a fluctuating course. In contrast to essential blepharospasm, symptoms often continue during sleep and can provoke insomnia. Emotion and stress tend to exacerbate facial twitching. Ear clicks can occur which resolve with treatment of the HFS (Rudzinska et al., 2010). Although benign, HFS can be disabling because of social embarrassment and excessive closure of the affected eye, interfering with vision. Symptoms can progress over time and facial weakness may develop independent from botulinum neurotoxin (BoNT) therapy. Hypertension is thought to be a risk factor for the development of HFS (Oliveira et al., 1999).

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Banik, R, Miller, NR (2004). Chronic myokymia limited to the eyelid is a benign condition. J Neuroophthalmol, 24, 290–2.CrossRefGoogle ScholarPubMed
Boghen, DR, Lesser, RL (2000). Blepharospasm and hemifacial spasm. Curr Treat Options Neurol 2, 393–400.CrossRefGoogle ScholarPubMed
Brin, MF, Fahn, S, Moskowitz, C et al. (1987). Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord, 2, 237–54.CrossRefGoogle ScholarPubMed
Cakmur, R, Ozturk, V, Uzunel, F, Donmez, B, Idiman, F (2002). Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol, 249, 64–8.CrossRefGoogle ScholarPubMed
Cannon, PS, MacKenzie, KR, Cook, AE, Leatherbarrow, B (2010). Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm. Clin Exp Ophthalmol, 38, 688–91.CrossRefGoogle ScholarPubMed
Colakoglu, BD, Cakmur, R, Uzunel, F (2011). Is it always necessary to apply botulinum toxin into the lower facial muscles in hemifacial spasm?: a randomized, single -blind, crossover trial. Eur Neurol, 65, 286–90.CrossRefGoogle ScholarPubMed
Elston, JS (1986). Botulinum toxin treatment of hemifacial spasm. J Neurol Neurosurg Psychiatry, 49, 827–9.CrossRefGoogle ScholarPubMed
Elston, JS (1992). The management of blepharospasm and hemifacial spasm. J Neurol, 239, 5–8.CrossRefGoogle ScholarPubMed
Flanders, M, Chin, D, Bogden, D (1993). Botulinum toxin: preferred treatment for hemifacial spasm. Eur Neurol, 33, 316–19.CrossRefGoogle ScholarPubMed
Frei, KP, Truong, DD (2008). Hemifacial spasm producing tremor-like movements of the head. J Neurol Sci, 273, 133–4.CrossRefGoogle Scholar
Frei, K, Truong, DD, Dressler, D (2006). Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations. Eur J Neurol, 13(Suppl 1), 30–5.CrossRefGoogle ScholarPubMed
Jitpimolmard, S, Tiamkao, S, Laopaiboon, M (1998). Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry, 64, 751–7.CrossRefGoogle ScholarPubMed
Lagalla, G, Logullo, F, DiBella, P, Highishipour, R, Provinciali, L (2010). Familial hemifacial spasm and determinants of late onset. Neurol Sci, 31, 17–22.CrossRefGoogle ScholarPubMed
Linder, JS, Edmonson, BC, Laquis, SJ, Drewry, RD, Fleming, JC (2002). Skin cooling before periocular botulinum toxin A injection. Ophthal Plast Reconstr Surg, 18, 441–2.CrossRefGoogle ScholarPubMed
Mezaki, T, Kaji, R, Kimura, J, Ogawa, N (1999). Treatment of hemifacial spasm with type A botulinum toxin (AGN 191622): a dose finding study and the evaluation of clinical effect with electromyography. No To Shinkei, 51, 427–32.Google ScholarPubMed
Miller, LE, Miller, VM (2012). Safety and effectiveness of microvascular decompression for treatment of hemifacial spasm: a systematic review. Br J Neurosurg, 26, 438–44.CrossRefGoogle ScholarPubMed
Miwa, H, Mizuno, Y, Kondo, T (2002). Familial hemifacial spasm: report of cases and review of the literature. J Neurol Sci, 193, 97–102.CrossRefGoogle Scholar
Oliveira, LD, Cardoso, F, Vargas, AP (1999). Hemifacial spasm and arterial hypertension. Mov Disord, 14, 832–5.3.0.CO;2-7>CrossRefGoogle ScholarPubMed
Park, YC, Lim, JK, Lee, DK, Yi, SD (1993). Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci, 8, 334–40.CrossRefGoogle ScholarPubMed
Price, J, Farish, S, Taylor, H, O’Day, J (1997). Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology, 104, 865–8.CrossRefGoogle ScholarPubMed
Roggenkamper, P, Laskawi, R, Damens, W, Schroeder, M, Nuessgens, Z (1994). Orbicular synkinesis after facial paralysis: treatment with botulinum toxin. Doc Ophthalmol, 86, 395–402.CrossRefGoogle ScholarPubMed
Rudzinska, M, Wojcik, M, Szczudilik, A (2010). Hemifacial spasm non-motor and motor-related symptoms and their response to botulinum toxin therapy. J Neural Transm, 117, 765–72.CrossRefGoogle ScholarPubMed
Ryu, H, Yamamoto, S, Miyamoto, T (1998). Atypical hemifacial spasm. Acta Neurochir (Wien), 140, 1173–6.CrossRefGoogle ScholarPubMed
Soylev, MF, Kocak, N, Kuvaki, B, Ozkan, SB, Kir, E (2002). Anesthesia with EMLA cream for botulinum A toxin injection into eyelids. Ophthalmologica, 216, 355–8.CrossRefGoogle ScholarPubMed
Tan, EK, Chan, LL, Koh, KK (2004). Coexistent blepharospasm and hemifacial spasm: overlapping pathophysiologic mechanism?J Neurol Neurosurg Psychiatry, 75, 494–6.CrossRefGoogle ScholarPubMed
Tousi, B, Perumal, JS, Ahuja, K, Ahmed, A, Subramanian, T (2004). Effects of botulinum toxin-B (BTX-B) injections for hemifacial spasm. Parkinsonism Relat Disord, 10, 455–6.CrossRefGoogle ScholarPubMed
Van den Bergh, P, Francart, J, Mourin, S, Kollman, P, Laterre, EC (1995). Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve, 18, 720–9.CrossRefGoogle ScholarPubMed
Wang, A, Jankovic, J (1998). Hemifacial spasm: clinical findings and treatment. Muscle Nerve, 21, 1740–7.3.0.CO;2-V>CrossRefGoogle ScholarPubMed
Yoshimura, DM, Aminoff, MJ, Tami, TA, Scott, AB (1992). Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve, 15, 1045–9.CrossRefGoogle ScholarPubMed
Yu, YL, Fong, KY, Chang, CM (1992). Treatment of idiopathic hemifacial spasm with botulinum toxin. Acta Neurol Scand, 85, 55–7.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×